Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Anaplastic lymphoma kinase Stories

2014-03-26 16:25:46

- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven...

2014-02-25 14:34:50

Results Support Need for Combined Testing The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor. The discovery of ALK rearrangement in about 1% to 7%...

2014-01-29 13:16:56

A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rates...

2013-12-18 11:26:28

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients. “When you have known oncogenes that are already targeted by FDA-approved drugs, it just made sense...

2013-10-21 13:15:33

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity,...

2013-09-11 12:24:27

VENTANA ALK (D5F3) IHC assay will aid in the identification of patients for Pfizer's XALKORI in China TUCSON, Ariz., Sept. 11, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry (IHC) assay by the Chinese Food and Drug Administration (CFDA) as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI® (crizotinib). The...

2013-09-10 23:02:58

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. Aurora, Colo. (PRWEB) September 10, 2013 A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The...

2013-07-23 16:23:51

ROUND ROCK, Texas, July 23, 2013 /PRNewswire/ -- A recent recall by a major manufacturer of Albumin Saline with Phenol (ABS) and Normal Saline with Phenol (NSP) products due to glass delamination has led to inaccurate claims of an "industry wide" recall of injectable pharmaceutical products in the allergy industry. ALK, a leading company focusing on allergy treatment, is pleased to announce that the entire ALK portfolio of products is not affected by this recall. ABS and NSP are used...

2013-06-25 19:17:47

Could be reliable and cost-effective diagnostic approach in lung cancer ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors. Development of robust and reliable laboratory tests for predictive biomarkers is essential to select appropriate patients for targeted therapy....

2013-06-03 12:28:53

- Investigational compound LDK378 is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC) EAST HANOVER, N.J., June 3, 2013 /PRNewswire/ -- Novartis today announced data on its investigational compound LDK378 showing a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated...